Matthew Hewitt
Stock Analyst at Craig-Hallum
(2.12)
# 3,056
Out of 5,182 analysts
5
Total ratings
60%
Success rate
8.04%
Average return
Main Sectors:
Stocks Rated by Matthew Hewitt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYRX Cryoport | Initiates: Buy | $15 | $9.64 | +55.60% | 1 | Mar 30, 2026 | |
| APYX Apyx Medical | Maintains: Buy | $5 → $6 | $3.88 | +54.64% | 1 | Mar 11, 2026 | |
| CERT Certara | Initiates: Buy | $16 | $5.79 | +176.34% | 1 | Sep 29, 2025 | |
| LFCR Lifecore Biomedical | Maintains: Buy | $8 → $10 | $4.94 | +102.43% | 2 | Nov 22, 2024 |
Cryoport
Mar 30, 2026
Initiates: Buy
Price Target: $15
Current: $9.64
Upside: +55.60%
Apyx Medical
Mar 11, 2026
Maintains: Buy
Price Target: $5 → $6
Current: $3.88
Upside: +54.64%
Certara
Sep 29, 2025
Initiates: Buy
Price Target: $16
Current: $5.79
Upside: +176.34%
Lifecore Biomedical
Nov 22, 2024
Maintains: Buy
Price Target: $8 → $10
Current: $4.94
Upside: +102.43%